Puma Biotechnology Inc (PBYI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has a cash flow conversion efficiency ratio of 0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.42 Million) by net assets ($130.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Puma Biotechnology Inc to assess the company's strategic physical and investment asset allocation.
Puma Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See PBYI net assets for net asset value and shareholders' equity analysis.
Puma Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puma Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capita PLC
LSE:CPI
|
-0.069x |
|
Jiangsu Aoyang Technology Ltd
SHE:002172
|
0.171x |
|
Kneat.com Inc
TO:KSI
|
-0.047x |
|
Samkang M&T Co.Ltd
KQ:100090
|
0.132x |
|
Jiangsu Chunlan Refrigerating Equipment Stock Co Ltd
SHG:600854
|
0.006x |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
-0.058x |
|
Cadiz Inc
NASDAQ:CDZI
|
-0.298x |
|
Myoung Shin Industrial Co Ltd
KO:009900
|
0.115x |
Annual Cash Flow Conversion Efficiency for Puma Biotechnology Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Puma Biotechnology Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.34 Million | $41.80 Million | 0.321x | -24.08% |
| 2024-12-31 | $92.12 Million | $38.92 Million | 0.422x | -16.41% |
| 2023-12-31 | $53.44 Million | $27.01 Million | 0.505x | +169.00% |
| 2022-12-31 | $21.61 Million | $-15.83 Million | -0.732x | +91.32% |
| 2021-12-31 | $-2.45 Million | $20.65 Million | -8.442x | -6180.06% |
| 2020-12-31 | $-5.95 Million | $800.00K | -0.134x | -110.49% |
| 2019-12-31 | $17.46 Million | $22.38 Million | 1.281x | +282.40% |
| 2018-12-31 | $34.31 Million | $-24.10 Million | -0.703x | +78.29% |
| 2017-12-31 | $53.30 Million | $-172.50 Million | -3.236x | -379.22% |
| 2016-12-31 | $209.82 Million | $-141.70 Million | -0.675x | +9.95% |
| 2015-12-31 | $206.01 Million | $-154.50 Million | -0.750x | -13.71% |
| 2014-12-31 | $117.05 Million | $-77.20 Million | -0.660x | -0.63% |
| 2013-12-31 | $83.99 Million | $-55.05 Million | -0.655x | -92.03% |
| 2012-12-31 | $128.91 Million | $-44.00 Million | -0.341x | -916.91% |
| 2011-12-31 | $54.37 Million | $-1.83 Million | -0.034x | +99.97% |
| 2009-12-31 | $138.00 | $-16.82K | -121.848x | -2340.50% |
| 2008-12-31 | $-2.18K | $-11.83K | 5.438x | -- |
| 2007-12-31 | $0.00 | $-15.09 Million | x | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more